Investor Presentation Q1 2023

150 Investor presentation First three months of 2023 Novo NordiskⓇ In 2022, more than 5 million people with diabetes were reached with access and affordability initiatives. 5.5 out of 36.3 million people were reached with access and affordability initiatives Million patients 36.3 5.5 30.8 J A number of focused programmes (as of full year 2022) Access to Insulin Commitment Changing Diabetes® in Children Vulnerability assessments . • 3 USD ceiling price for human insulin vial offered to 76 low- and middle-income countries, reaching ~1.8 million patients in 2022 2.5 million patients reached at or below the ceiling price in countries outside the commitment¹ ~41,000 children reached at the end of 2022, across 26 countries in three regions (APAC, LATAM and SEEMEA) More than half of the 9,187 newly enrolled children reached through expansion in Ethiopia, Sudan, Kenya and Uganda Ensure availability of affordable insulin for vulnerable patients Completed vulnerability assessments, resulting in 25 plans being implemented across APAC, LATAM and SEEMEA regions Patients reached in 2022 US affordability offerings Suite of affordability offerings including unbranded biologics, My $99 insulin and more In 2022, DKK 261 billion were provided in discounts and rebates in the US, amounting to 75% of US gross sales 1. The access and affordability programmes are not mutually exclusive, implying that the sum of the reach of each programme cannot be interpreted as the total unique number of people with diabetes reached. More info on Novo Nordisk access and affordability programmes can be found at: Access & affordability (novonordisk.com). 2. Changing Diabetes in Children is a public-private partnership between the International Society for Paediatric and Adolescent Diabetes, the World Diabetes Foundation, Roche, and Novo Nordisk.

View entire presentation